中药安全性事件的危险因素与防治对策

doi:10.7501/j.issn.1674-6376.2024.04.021

温馨提示：建议您使用Chrome80、火狐74+、IE9+浏览器，当您的浏览器版本过低，可能会影响部分功能正常使用。

主办：天津药物研究院中国药学会

微信公众号

网站二维码

2025年6月14日 22:22 星期六

首页 > 过刊浏览>2024年第47卷第4期 >2024,47(4):873-888. DOI:10.7501/j.issn.1674-6376.2024.04.021

中药安全性事件的危险因素与防治对策

姚一帆
姚一帆
河南科技大学临床医学院河南科技大学第一附属医院内分泌代谢中心河南省罕见病重点实验室洛阳市临床多组学与转化医学重点实验室，河南洛阳 471003
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
孔娇
孔娇
浙江大学药学院药物代谢和药物分析研究所，浙江杭州 310058
通讯作者.
Email: Kj2022@zju.edu.cn
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
刘传鑫
刘传鑫
河南科技大学临床医学院河南科技大学第一附属医院内分泌代谢中心河南省罕见病重点实验室洛阳市临床多组学与转化医学重点实验室，河南洛阳 471003
通讯作者.
Email: 15222003775@163.com
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找

Risk factors and prevention and control countermeasures of traditional Chinese medicine safety incidents

YAO Yifan
YAO Yifan
Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
KONG Jiao
KONG Jiao
College of Pharmaceutical Sciences, Institute of Drug Metabolism and Drug Analysis, Zhejiang University, Hangzhou 310058, China
Contact Author.
Email: Kj2022@zju.edu.cn
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
LIU Chuanxin
LIU Chuanxin
Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China
Contact Author.
Email: 15222003775@163.com
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找

发布日期：2024-04-09

摘要
图/表
访问统计
PDF预览
参考文献
相似文献
引证文献
附件

[关键词]

马兜铃酸 ; 雷公藤 ; 八角莲 ; 槟榔 ; 仙灵骨葆胶囊 ; 鱼腥草注射剂 ; 安全事件 ; 合理用药

[摘要]

回顾马兜铃酸、雷公藤、八角莲、槟榔、仙灵骨葆胶囊、鱼腥草注射剂、双黄连注射剂等引发的中药安全性事件，旨在探讨影响中药安全性的危险因素，对中药毒性成分、生产工艺、储藏条件、体质差异、给药剂量、风险管控等方面存在的安全性问题进行探讨，提出加强源头控制以确保质量合格、探明配伍机制以增效减毒、提高生产标准以推进质量统一、完善法规政策以加强管控、健全安全性评价体系以确保质量达标等建议，以期为促进临床合理用药、减少中药安全性事件提供帮助。

[Key word]

aristolochic acids ; Tripterygium wilfordii ; Dysosma versipellis ; Areca catechu ; Xianling Gubao Capsule ; Yuxingcao Injection ; safety incidents ; rational administration of drug

[Abstract]

This paper reviews the safety incidents of traditional Chinese medicine, caused by such as aristolochic acids, Tripterygium wilfordii, Dysosma versipellis, Areca catechu, Xianling Gubao Capsule, Yuxingcao Injection and Shuanghuanglian Injection, to explore the risk factors affecting the safety of traditional Chinese medicine. This paper reviews the safety problems existing in the toxic components, production process, storage conditions, physical differences, dosage, risk management and control of traditional Chinese medicine, and puts forward suggestions such as strengthening source control to ensure that the quality is qualified, improving production standards to promote quality unification, improving laws and policies to strengthen control, and improving the safety evaluation system to ensure that the quality is up to standard, so as to provide help for promoting the rational use of clinical drugs and reducing the safety incidents of traditional Chinese medicine.

[中图分类号]

[基金项目]

国家自然科学基金资助项目（82204938）

引用本文 / Get Citation

姚一帆,孔娇,刘传鑫.中药安全性事件的危险因素与防治对策[J].药物评价研究,2024,47(4):873-888

分享 / Share

文章指标 / Article Metrics

点击次数: 591

下载次数: 1364

Html阅读次数: 0

引用次数: 0

历史 / History

收稿日期: 2023-09-09

在线发布日期: 2024-04-09

出版日期: 2024-04-08

[1] 赵旭,吴承钊,王伽伯,等.新突发传染病(新冠肺炎)中医药防治策略:系统辨靶论治[J].中国现代中药, 2022, 24(11):2055-2060.Zhao X, Wu C Z, W J B, et al.Strategies of traditional Chinese medicine for the prevention and treatment of emerging infectious diseases (COVID-19):Targetcombined holistic treatment[J].Mod Chin Med, 2022, 24(11):2055-2060.

[2] 孙利辉,丁樱,韩姗姗,等.基于文献挖掘探讨中药减轻雷公藤雌性生殖毒性的规律分析[J].中草药, 2023, 54(6):1886-1895.Sun L H, Ding Y, Han S S, et al.Analysis of regularity of traditional Chinese medicine for attenuating female reproductive toxicity of Tripterygium wilfordii based on literature mining[J].Chin Tradit Herb Drugs, 2023, 54(6):1886-1895.

[3] 朱文静,张立丹,周玥,等.马兜铃酸及马兜铃科中药临床使用风险差异研究[J].中国药物警戒, 2022, 19(11):1213-1217.Zhu W J, Zhang L D, Zhou Y, et al.Risk difference between aristolochic acid and clinical use of traditional Chinese medicines in Aristolochiaceae[J].Chin J Pharmacovig, 2022, 19(11):1213-1217.

[4] Ng A W T, Poon S L, Huang M N, et al.Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia[J].Sci Transl Med, 2017, 9(412):eaan6446.

[5] 张美玉,李连达.鱼腥草注射液不良反应原因分析和对策[J].中药药理与临床, 2010, 26(4):77-81.Zhang M Y, Li L D.Analysis on the causes and countermeasures of adverse reactions of Houttuynia Injection[J].Pharmacol Clin Chin Mater Med, 2010, 26(4):77-81.

[6] 王书新,潘邓记,唐洲平.八角莲中毒致多发性周围性神经病1例报告[J].神经损伤与功能重建, 2010, 5(6):463-463.Wang S X, Pan D J, Tang Z P.A case report of multiple peripheral neuropathy caused by Dysosma versipellis[J].Neural Injury Funct Reconstr, 2010, 5(6):463-463.

[7] 唐伟,石庆平,马涛,等.双黄连注射剂不良反应发生率的Meta分析[J].中国中药杂志, 2016, 41(14):2732-2742.Tang W, Shi Q P, Ma T, et al.Meta-analysis on incidence of adverse drug reaction induced by Shuanghuanglian Injection[J].China J Chin Mater Med, 2016, 41(14):2732-2742.

[8] 何康婧,高增平,尹丽梅,等.雷公藤多苷的药理毒理作用研究进展[J].中国实验方剂学杂志, 2020, 26(1):196-204.He K J, Gao Z P, Yin L M, et al.Pharmacological and toxicological effect of Tripterygii Radix et Rhizoma polyglycosides[J].Chin J Exp Tradit Med Form, 2020, 26(1):196-204.

[9] 黄迎,刘亚蕾,马润然,等.仙灵骨葆相关肝损伤的临床病例分析及拆方实验研究[J].药学学报, 2021, 56(1):266-273.Huang Y, Liu Y L, Ma R R, et al.Clinical case analysis and disassembled prescription study of liver injury related to Xianling Gubao[J].Acta Pharm Sin, 2021, 56(1):266-273.

[10] 肖小河,柏兆方,王伽伯,等.中药安全性评价与药物警戒[J].科学通报, 2021, 66(4):407-414.Xiao X H, Bai Z F, Wang J B, et al.Traditional Chinese medicine (TCM) safety evaluation and pharmacovigilance[J].Chin Sci Bull, 2021, 66(4):407-414.

[11] 孔娇,田悦,刘传鑫,等."量-权-证"网络毒理学的提出与应用:以八角莲醇提液致肝毒性为例[J].中国中药杂志, 2022, 47(2):511-527.Kong J, Tian Y, Liu C X, et al.Mechanism of hepatotoxicity induced by ethanol extract of Dysosma versipellis based on "quantity-weight-evidence" network toxicology[J].China J Chin Mater Med, 2022, 47(2):511-527.

[12] 柏兆方,王伽伯,肖小河.中药毒性认知创新与安全精准用药[J].中国中药杂志, 2022, 47(10):2557-2564.Bai Z F, Wang J B, Xiao X H.Cognition innovation of toxicity of Chinese medicine and safe and precise medication[J].China J Chin Mater Med, 2022, 47(10):2557-2564.

[13] 刘传鑫,孔娇.体质毒理学:中药安全性评价的新方向[J].世界科学技术:中医药现代化, 2023, 25(12):3776-3784.Liu C X, Kong J.Constitution-based toxicology:A new perspective of study for assessing the safety of traditional Chinese medicine[J].World Sci Technol:Mod Traditi Chin Med, 2023, 25(12):3776-3784.

[14] 刘静,郭日新,戴忠,等.马兜铃酸类成分研究进展[J].世界科学技术:中医药现代化, 2019, 21(7):1280-1286.Liu J, Guo R X, Dai Z, et al.Research progress on aristolochic acids[J].World Sci Technol:Mod Traditi Chin Med, 2019, 21(7):1280-1286.

[15] 高月,肖小河,朱晓新,等.马兜铃酸的毒性研究及思考[J].中国中药杂志, 2017,42(21):4049-4053.Gao Y, Xiao X H, Zhu X X, et al.Study and opinion on toxicity of aristolochic acid[J].China J Chin Mater Med, 2017,42(21):4049-4053.

[16] 田婧卓,梁爱华,刘靖,等.从马兜铃酸含量影响因素探讨含马兜铃酸中药的风险控制[J].中国中药杂志, 2017, 42(24):4679-4686.Tian J Z, Liang A H, Liu J, et al.Risk control of traditional Chinese medicines containing aristolochis acids (AAs) based on influencing factors of content of AAs[J].China J Chin Mater Med, 2017, 42(24):4679-4686.

[17] 陈文娟,吴晶金.雷公藤毒性及中药配伍减毒研究进展[J].中成药, 2023, 45(2):499-503.Chen W J, Wu J J.Research progress of the toxicity ofTripterygium wilford and attenuation of compatibility of Chinese medicine[J].Chin Tradit Pat Med, 2023, 45(2):499-503.

[18] 田雅格,苏晓慧,刘立玲,等.近20年来雷公藤肝毒性研究概述[J].中国中药杂志, 2019, 44(16):3399-3405.Tian Y G, Su X H, Liu L L, et al.Overview of hepatotoxicity studies on Tripterygium wilfordii in recent 20 years[J].China J Chin Mater Med, 2019, 44(16):3399-3405.

[19] 麻利杰,张博,侯富国,等.《中药饮片临床应用规范》对中药饮片处方审核的指导作用分析[J].医药导报, 2023, 42(3):366-370.Ma L J, Zhang B, Hou F G, et al.Analysis of the guidance of specification for the clinical application of Chinese herbal pieces in prescription review practice of Chinese herbal decoction pieces[J].Herald Med, 2023, 42(3):366-370.

[20] Singh N, Agrawal P.A comprehensive review on the pharmacognostic and toxicological profile of Podophyllum peltatum (Bajiaolian)[J].Pharmacol Res:Mod Chin Med, 2024, 10100353-10100353.

[21] 方红丽,叶小军,王小川,等.中毒性脑病35例临床特征和预后分析[J].中华危重症医学杂志:电子版, 2020, 13(3):207-210.Fang H L, Ye X J, Wang X C, et al.Clinical characteristics and outcomes of 35 cases of toxic encephalopathy[J].Chin J Crit Care Med:Elec Ed, 2020, 13(3):207-210.

[22] Tan X M, Zhou Y Q, Zhou X L, et al.Diversity and bioactive potential of culturable fungal endophytes of Dysosma versipellis:A rare medicinal plant endemic to China[J].Sci Rep, 2018, 8(1):5929-5929.

[23] 沈叶菊,李小民.1例八角莲中毒患者救治体会[J].医学信息, 2015(14):240-240.Shen Y J, Li X M.Treatment experience of a patient with Dysosma versipellis poisoning[J].Med Inform, 2015(14):240-240.

[24] 李雪梅,肖斯婷,高晓新,等.红金消结胶囊小鼠口服给药急性毒性拆方研究[J].首都食品与医药, 2024, 31(3):11-14.Li X M, Xiao S T, Gao X X, et al.Acute toxicity of Hongjinxiaojie Capsule after oral administration in mice[J].Capital Med, 2024, 31(3):11-14.

[25] Liu C X, Zhang C M, He T, et al.Study on potential toxic material base and mechanisms of hepatotoxicity induced by Dysosma versipellis based on toxicological evidence chain (TEC) concept[J].Ecotoxicol Environ Saf, 2020, 190:110073-110073.

[26] Kong J, Kui H, Tian Y, et al.Nephrotoxicity assessment of podophyllotoxin-induced rats by regulating PI3K/Akt/mTOR-Nrf2/HO1 pathway in view of toxicological evidence chain (TEC) concept[J].Ecotoxicol Environ Saf, 2023, 264:115392-115392.

[27] Duan J J, Sun J X, Jiang T, et al.Podophyllotoxinmediated neurotoxicity via the microbiota-gut-brain axis in SD rats based on the toxicological evidence chain (TEC) concept[J].Sci Total Environ, 2023, 907:168106-168106.

[28] 马君,江露,陈虎,等.中药八角莲的研究进展[J].湖北医药学院学报, 2020, 39(1):96-100.Ma J, Jiang L, Chen H, et al.Research progress in Chinese herbal medicine Dysosma versipellis[J].J Hubei Univ Med, 2020, 39(1):96-100.

[29] 薛凯,李敏.国家重点保护野生植物介绍:八角莲属[J].生命世界, 2023(8):94-95.Xue K, Li M.National key protected wild plants:Dysosma[J].Life World, 2023(8):94-95.

[30] Yi H, Yuan L G, Mao Y S.Moving forward:The nationwide advertising ban of Areca nut in China[J].Oral Oncol, 2021, 122:105590-105590.

[31] 周明玺,郭亦晨,李珂,等.槟榔活性成分及药理毒理作用研究进展[J].中成药, 2022, 44(3):878-883.Zhou M X, Guo Y C, Li k, et al.Research progress on modern chemical constituents and pharmacological activities and toxicity of Areca catechu L.[J].Chin Tradit Pat Med, 2022, 44(3):878-883.

[32] 易攀,汤嫣然,周芳,等.槟榔的化学成分和药理活性研究进展[J].中草药, 2019, 50(10):2498-2504.Yi P, Tang Y R, Zhou F, et al.Research progress on chemical constituents and pharmacological activities of Areca catechu L.[J].Chin Tradit Herb Drugs, 2019, 50(10):2498-2504.

[33] 杨雅蛟,孔维军,孙兰,等.槟榔化学成分和药理作用及临床应用研究进展[J].世界科学技术:中医药现代化, 2019, 21(12):2583-2591.Yang Y J, Kong W J, Sun L, et al.Research progress on chemical composition and pharmacological effect and clinical application of Areca catechu[J].Mod Tradit Chin Med Mater Med:World Sci Technol, 2019, 21(12):2583-2591.

[34] 佘颖.叫停槟榔广告很有必要[J].人民周刊, 2021(18):19.Yu Y.It is necessary to stop Areca catechu L.advertising[J].People's Week, 2021(18):19.

[35] Marques M M, Beland F A, Lachenmeier D W, et al.Carcinogenicity of acrolein, crotonaldehyde, and arecoline[J].Lancet Oncol, 2020, 22(1):19-20.

[36] 梁焕宴,冀沛然,弓宝,等.槟榔的药用历史及其应用现状[J].中草药, 2024, 55(2):678-687.Liang H Y, Ji P R, Gong B, et al.Medicinal history and current application status of Arecae Semen[J].Chin Tradit Herb Drugs, 2024, 55(2):678-687.

[37] Kong D D, Wang G F, Tang Y, et al.Potential health risk of Areca nut consumption:Hazardous effect of toxic alkaloids and aflatoxins on human digestive system[J].Food Res Int, 2022, 162(PA):112012-112012.

[38] 孔丹丹,李歆悦,赵祥升,等.药食两用槟榔的国内外研究进展[J].中国中药杂志, 2021, 46(5):1053-1059.Kong D D, Li X Y, Zhao X S, et al.Domestic and international research progress of edible and medicinal Arecae Semen[J].China J Chin Mater Med, 2021, 46(5):1053-1059.

[39] 朱春雾,余雪君,孙鑫,等.仙灵骨葆胶囊肝毒性研究进展[J].中国药物警戒, 2023, 20(5):496-499.Zhu C W, Yu X J, Sun X, et al.Overview of hepatotoxicity of Xianling Gubao Capsules[J].Chin J Pharmacovig, 2023, 20(5):496-499.

[40] 张悦,王佳艺,刘慧敏,等.淫羊藿及其制剂主要化学成分与肝损伤作用研究进展[J].中草药, 2023, 54(21):7213-7221.Zhang Y, Wang J Y, Liu H M, et al.Research progress on main chemical constituents and liver injury effects of Epimedii Folium and its preparations[J].Chin Tradit Herb Drugs, 2023, 54(21):7213-7221.

[41] 高欢欢,章轶立,谢雁鸣,等.仙灵骨葆口服制剂的不良反应信号挖掘研究[J].中国药物警戒, 2020, 17(5):284-289.Gao H H, Zhang T L, Xie Y M, et al.Study on adverse drug reactions signal early warning of Xianling Gubao Capsule and tablet[J].Chin J Pharmacovig, 2020, 17(5):284-289.

[42] 张福明,石垚,韩园园,等.鱼腥草治疗病毒性肺炎作用机制的"成分-靶点-通路"多层次互作网络研究[J].药物评价研究, 2022, 45(11):2188-2199.Zhang F M, Shi Y, Han Y Y, et al.Study on componenttarget-pathway multiple interactive network to reveal mechanism of Houttuynia cordata in treatment of viral pneumonia[J].Drug Eval Res, 2022, 45(11):2188-2199.

[43] 郝利军,梁爱华,宋经元.鱼腥草注射液原料药材资源与质量控制研究进展[J].世界中医药, 2020, 15(5):657-662.Hao L J, Liang A H, Song J Y.Research progress on the raw material resources and quality control of Houttuynia cordata Injection[J].World Chin Med, 2020, 15(5):657-662.

[44] 李秀惠,刘清泉.北京市新型冠状病毒肺炎中医药防治方案(试行第五版)[J].北京中医药, 2020, 39(7):655-656.Li X H, Liu Q Q.Beijing prevention and treatment program of TCM for COVID-19(Trial 5th Edition)[J].Beijing J Tradit Chin Med, 2020, 39(7):655-656.

[45] 国家药监局:4周岁及以下儿童禁用双黄连注射剂[J].中医药导报, 2018, 24(13):4. The National Medical Products Administration:Children aged 4 and under are prohibited from Double Coptis Injection[J]. Guid J Tradit Chin Med Pharm, 2018, 24(13):4.

[46] 岑敏,赵丹,熊婷,等.儿童患者静脉滴注莲必治注射液致急性肾损伤的危险因素分析[J].儿科药学杂志, 2020, 26(1):23-26. Cen M, Zhao D, Xiong T, et al. Risk factors for acute kidney injury induced by intravenous infusion of Lianbizhi Injection in children[J]. J Pediatr Pharm, 2020, 26(1):23-26.

[47] 胡中慧.莲必治注射液安全性再评价研究[D].北京:中国人民解放军军事医学科学院, 2010. Hu Z H. Evaluation research of security on Lianbizhi Injection[D]. Beijing:Academy of Military Sciences, 2010.

[48] 李辉,马仕洪,王兰,等.中药注射剂安全性及其无菌保障体系的现状与思考[J].中成药, 2022, 44(9):2939-2943. Li H, Ma S H, Wang L, et al. Current status and reflection on the safety of the traditional Chinese medicine injections and aseptic assurance system[J]. Chin Tradit Pat Med, 2022, 44(9):2939-2943.

[49] 李春晓,杨玉晴,凌霄,等.基于混合方法探讨中药注射剂临床疗效评价指标的筛选[J].中医杂志, 2023, 64(22):2291-2294. Li C X, Yang Y Q, Ling X, et al. Screening of clinical efficacy evaluation indicators for traditional Chinese medicine injections based on mixed method research[J]. J Tradit Chin Med, 2023, 64(22):2291-2294.

[50] 孟驿佳,康乐,王媛,等. 2020年版《中国药典》(一部)有毒中药毒性成分及毒性特点分析[J].中药药理与临床, 2023, 39(1):99-104. Meng Y J, Kang L, Wang Y, et al. Toxic components and toxicity characteristics of toxic Chinese herbal medicines in the 2020 Edition of Chinese Pharmacopoeia (Volume Ⅰ)[J]. Pharmacol Clin Chin Mater Med, 2023, 39(1):99-104.

[51] 杨鹤年,张津铖,吴宿慧,等.中药配方颗粒制备工艺、质量评价、与传统汤剂一致性的研究现状分析[J].中国实验方剂学杂志, 2023, 29(8):266-274. Yang H N, Zhang J C, Wu S H, et al. Research on preparation process and quality evaluation of traditional Chinese medicine dispensing granules and its consistency with traditional decoction:A review[J]. Chin J Exp Tradit Med Form, 2023, 29(8):266-274.

[52] 程云霞,刘震营,徐博,等.中药材贮藏期虫蛀现象的研究现状[J].中国中药杂志, 2023, 48(19):5152-5161. Cheng Y X, Liu Z Y, Xu B, et al. Research status of insect infestation of Chinese medicinal materials during storage[J]. China J Chin Mater Med, 2023, 48(19):5152-5161.

[53] 李耀磊,张冰,张晓朦,等.基于毒害成分的中药临床安全性评价与思考[J].中国药物警戒, 2021, 18(6):520-524. Li Y L, Zhang B, Zhang X M, et al. Evaluation and consideration of clinical safety of traditional Chinese medicine based on toxic components[J]. Chin J Pharmacovig, 2021, 18(6):520-524.

[54] 付璐,金艳,彭华胜,等.基于本草古籍的中药毒性分级及影响因素探讨[J].中国药物警戒, 2022, 19(4):349-352. Fu L, Jin Y, Peng H S, et al. Classification and influencing factors of toxicity of Chinese medicine based on ancient books of materia medica[J]. Chin J Pharmacovig, 2022, 19(4):349-352.

[55] Fallahzadeh R A, Ghaneian M T, Miri M, et al. Spatial analysis and health risk assessment of heavy metals concentration in drinking water resources[J]. Environ Sci Pollut Res, 2017, 24(32):24790-24802.

[56] Du R H, Zhang Y, Yao Y P. Influencing factors and biological control of aflatoxin contamination in peanuts[J]. Agric Biotechnol, 2018, 7(2):22-26.

[57] 刘静,朱炯,王翀,等. 2022年国家药品抽检中成药质量状况分析[J].中国现代中药, 2023, 25(10):2055-2060. Liu J, Zhu J, Wang C, et al. Quality analysis of Chinese patent medicines based on 2022 national drug sampling and inspection[J]. Mod Chin Med, 2023, 25(10):2055-2060.

[58] 王莹,刘丽娜,许玮仪,等. 2013-2021年药品抽检中药质量分析及抽检模式探讨[J].中国现代中药, 2022, 24(2):210-216. Wang Y, Liu L N, Xu W Y, et al. Quality analysis of Chinese medicine based on drug sampling inspection from 2013 to 2021 and discussion on sampling inspection mode[J]. Mod Chin Med, 2022, 24(2):210-216.

[59] 杨冰,杨陆,杨菊,等.新世纪20年:中药炮制装备的时空演变[J].中国中药杂志, 2022, 47(05):1177-1183. Yang B, Yang L, Yang J, et al. Twenty years in the 21st century:Temporal and spatial evolution of Chinese medicinal processing equipment[J]. China J Chin Mater Med, 2022, 47(05):1177-1183.

[60] 苏玮玮,李娟娟,余思洋,等.云南省2012-2019年乌头类植物中毒流行特征[J].中国热带医学, 2020, 20(7):666-669. Su W W, Li J J, Yu S Y, et al. Epidemic characteristics of aconite poisoning in Yunnan, 2012-2019[J]. China Tropical Med, 2020, 20(7):666-669.

[61] 王珂欣,高丽,秦雪梅,等.中药注射剂色差与安全性研究进展[J].中草药, 2019, 50(9):2219-2223. Wang K X, Gao L, Qin X M, et al. Research progress on chromatic aberration and safety of Chinese materia medica injection[J]. Chin Tradit Herb Drugs, 2019, 50(9):2219-2223

[62] 程云霞,刘伟,王凯,等.中药材贮藏过程中"走油"变质的影响因素品质评价及其机制研究进展[J].中国现代中药, 2022, 24(6):1134-1138. Cheng Y X, Liu W, Wang K, et al. Research advances in influencing factors, quality evaluation, and mechanisms of rancidness of Chinese medicinal materials during storage[J]. Mod Chin Med, 2022, 24(6):1134-1138.

[63] 唐文文.不同储藏环境下5种药材品质比较[J].中成药, 2022, 44(7):2214-2218. Tang W W. Quality comparison of five medicinal materials under different storage environments[J]. Chin Tradit Pat Med, 2022, 44(7):2214-2218.

[64] 漆凤梅,饶小勇,何雁,等.中药饮片真菌污染现状与分析[J].江西中医药大学学报, 2023, 35(5):123-128. Qi F M, Rao X Y, He Y, et al. Current situation and analysis of fungal contamination of traditional Chinese medicine pieces[J]. J Jiangxi Univ Tradit Chin Med, 2023, 35(5):123-128.

[65] 郭东晓,许丽丽,崔伟亮,等.关于构建中药材和饮片贮藏养护质量管理体系的思考[J].中药材, 2021, 44(9):2023-2027. Guo X D, Xu L L, Cui W L, et al. Considerations on constructing quality management system of slices storage and maintenance of Chinese medicinal materials and decoction[J]. J Chin Med Mater, 2021, 44(9):2023-2027.

[66] 叶向光,王赛寒,陶宁,等.储藏中药材木耳螨类污染调查及陆氏费索螨的形态观察[J].中国病原生物学杂志, 2020, 15(7):827-829. Ye X G, Wang S H, Tao N, et al. Study on mites breeding in stored fruiting bodies of Auricularia auricula and observation of Fessonia luensis (Acari:Smaridiidae)[J]. J Pathog Biol, 2020, 15(7):827-829.

[67] 张明,杨星辰,金丽,等. 122例中药制剂所致ADR特点及其影响因素[J].中成药, 2021, 43(8):2268-2271. Zhang M, Yang X C, Jin L, et al. Characteristics and influencing factors of 122 Cases of ARD of traditional Chinese medicine[J]. Chin Tradit Pat Med, 2021, 43(8):2268-2271.

[68] 国家药品不良反应监测年度报告(2022年)[J].中国药物警戒, 2023, 20(6):712-719. Annual report of national adverse drug reaction monitoring (2022)[J]. Chin J Pharmacovig, 2023, 20(6):712-719.

[69] 袁六六,朱景平,王米香.中药注射液致老年患者临床不良反应特点分析[J].临床心身疾病杂志, 2021, 27(1):102-105. Yuan L L, Zhu J P, Wang M X. Analysis of adverse reactions caused by traditional Chinese medicine injection in the elderly[J]. J Clin Psychosom Dis, 2021, 27(1):102-105.

[70] 张丽霞,黄远良,王莎莎,等.食物变态反应的中医病因病机探讨[J].江西中医药大学学报, 2016, 28(5):9-12. Zhang L X, Huang Y L, Wang S S, et al. An analysis of the etiology and pathogenesis of traditional Chinese medicine in food allergy[J]. J Jiangxi Univ Tradit Chin Med, 2016, 28(5):9-12.

[71] 刘呈艳,阮时宝.重剂中药治顽疾现状[J].福建中医药大学学报, 2014, 24(6):67-69. Liu C Y, Ruan S B. The status quo of heavy Chinese medicine in the treatment of stubborn diseases[J]. J Fujian Univ Tradit Chin Med, 2014, 24(6):67-69.

[72] 刘甜甜,巩颖,顾媛媛,等.从中医经典方剂剂型转变分析中药饮片处方总剂量[J].中国药物警戒, 2022, 19(10):1103-1106. Liu T T, Gong Y, Gu Y Y, et al. Total dosage of Chinese herbal pieces from changes of traditional Chinese medicine prescriptions[J]. Chin J Pharmacovig, 2022, 19(10):1103-1106.

[73] 胡晓怡,胡曼娜,吴莉娟,等.中药汤剂的量效关系与安全性探讨[J].当代医学, 2023, 29(4):191-194. Hu X Y, Hu M N, Wu L J, et al. Discussion on dose-effect relationship and safety of traditional Chinese medicine decoction[J]. Contemp Med, 2023, 29(4):191-194.

[74] 郑雁雪,王圆圆,王琳,等.中药配伍减毒增效的现代研究及思考[J].中草药, 2023, 54(2):386-395. Zheng Y X, Wang Y Y, Wang L, et al. Modern research and thinking on compatibility mechanism of reducing toxicity of traditional Chinese medicine[J]. Chin Tradit Herb Drugs, 2023, 54(2):386-395.

[75] 杨亮,王宇光,梁乾德,等.基于UPLC/Q-TOF-MS不同比例人参配伍藜芦增毒的物质基础及动物毒性关联性研究[J].质谱学报, 2012, 33(5):257-264. Yang L, Wang Y G, Liang Q D, et al. UPLC/Q-TOF-MS based the diversity of toxiferous composition of the toxicity of animals and in different combination of veratrum nigrum and ginseng[J]. J Chin Mass Spectro Soc, 2012, 33(5):257-264.

[76] 吕建平,张晓霞.中西药联用所致不良反应的临床分析[J].世界中医药, 2019, 14(3):754-757. Lyu J P, Zhang X X. Clinical analysis of adverse reactions caused by combination of chinese and western medicine[J]. World Chin Med, 2019, 14(3):754-757.

[77] 丁涛,张阳,纵横.从《伤寒论》太阳篇浅探张仲景"同病异治"与"异病同治"思想[J].中医药临床杂志, 2016, 28(10):1415-1417. Ding T, Zhang Y, Zong H. Discussion of "the Same Disease with Different Treatment" and "the Same Treatment for Different Diseases" thought of Zhang Zhongjin according to the thought of water-control in Shanghan Lun[J]. Clin J Tradit Chin Med, 2016, 28(10):1415-1417.

[78] 吴富甫,王戌,李蕙.从风寒湿热论治流行性感冒的可行性研究[J].中国中医药现代远程教育, 2022, 20(3):140-142. Wu F F, Wang X, Li H. A feasibility study of treating influenza based on wind, cold, dampness and heat[J]. Chin Med Mod Dist Edu China, 2022, 20(3):140-142.

[79] 顾志荣,葛斌,郑修丽,等.我国中成药临床应用指南类建设的现状、问题与建议[J].中国中医药信息杂志, 2023, 30(4):6-11. Gu Z R, Ge B, Zheng X L, et al. Status, Problems and recommendations of building of guidelines for clinical application of Chinese patent medicines in China[J]. Chin J Inform Tradit Chin Med, 2023, 30(4):6-11.

[80] 赵军宁.中药监管科学:助力更高水平的中药科学监管[J].中国药学杂志, 2023, 58(9):749-761. Zhao J N. TCM rugulatory science:Promote a higher level of scientific regulation of traditional Chinese medicine[J]. Chin Pharm J, 2023, 58(9):749-761.

[81] 王赵,金红宇,马双成.从市场抽验角度探讨中药配方颗粒质量标准相关问题[J].中草药, 2023, 54(3):677-687. Wang Z, Jin H Y, Ma S C. Discussion on quality standard of traditional Chinese medicine formula granules from perspective of sampling inspection[J]. Chin Tradit Herb Drugs, 2023, 54(3):677-687.

[82] 刘佳,杨宝,陈繁华,等.多个厂家维C银翘片中5种成分的含量测定结果分析[J].中国药房, 2016, 27(12):1680-1683. Liu J, Yang B, Chen F H, et al. Analysis on content determination of 5 components in vitamin C Yinqiao Tablet from multiple manufacturers[J]. China Pharm, 2016, 27(12):1680-1683.

[83] 郭丹,杨洋,史岚,等. 2017年至2021年上海市药品质量抽检不合格数据分析[J].药品评价, 2023, 20(1):10-13. Guo D, Yang Y, Shi L, et al. Analysis of the results of unqualified drug sampling and testing in Shanghai from 2017 to 2021[J]. Drug Eval, 2023, 20(1):10-13.

[84] 左甜甜,申明睿,张磊,等.中药中重金属及有害元素限量标准的制定及有关问题的思考[J].药物分析杂志, 2023, 43(4):701-711. Zuo T T, Shen M R, Zhang L, et al. Formulation of limit standards for heavy metals and harmful elements in TCMs and related reflections[J]. Chin J Pharm Anal, 2023, 43(4):701-711.

[85] 付婷婷,尹兴斌,蔡梦如,等.曲类中药的品种整理和标准现状分析[J].中国中药杂志, 2023, 48(10):2699-2712. Fu T T, Yin X B, Cai M R, et al. Current situation of varieties and standards of fermented Chinese medicine[J]. China J Chin Mater Med, 2023, 48(10): 2699-2712.

[86] 魏湘萍,白莉,苗明三.毒性中药分级变化的思考[J].中华中医药杂志, 2021, 36(4):2158-2161. Wei X P, Bai L, Miao M S. Thinking on the grading change of toxic Chinese medicine[J]. China J Tradit Chin Med Pharm, 2021, 36(4):2158-2161.

[87] 唐亚岚,蒋启华.中药注射剂说明书修订公告及备案现状分析[J].中国现代应用药学, 2021, 38(15):1882-1888. Tang Y L, Jiang Q H. Analysis of revision notifications of traditional Chinese medicine injection leaflets and relevant filed information[J]. Chin J Mod Appl Pharm, 2021, 38(15):1882-1888.

[88] 王晶. 2010-2020年我国中成药药品说明书修订情况分析[J].中国药房, 2021, 32(4):392-398. Wang J. Analysis on revision of Chinese patent medicine instructions in China from 2010 to 2020[J]. China Pharm, 2021, 32(4):392-398.

[89] 张冰,张晓朦,林志健,等. 《上市中成药说明书安全信息项目修订技术规范》系列团体标准[J].中国中药杂志, 2022, 47(2):285-294. Zhang B, Zhang X M, Lin Z J, et al. Series of group standards of technical specifications for revision of safety information in marketed Chinese patent medicine instructions[J]. China J Chin Mater Med, 2022, 47(2):285-294.

[90] 顾晓玲,王骏. 23份中药注射剂说明书修订内容的情况分析[J].中医药通报, 2022, 21(6):33-35. Gu X L, Wang J. Analysis the revised contents of twentythree instructions of traditional Chinese medicine injections[J]. Tradit Chin Med J, 2022, 21(6):33-35.

[91] 陈安琪,张洪雷,徐爱军.健康中国战略视域下中医药服务现状及对策研究[J].中医药导报, 2019, 25(19):25-28, 43. Chen A Q, Zhang H L, Xu A J. Research on the status quo of Chinese medicine service under the perspective of healthy China strategy[J]. Guid J Tradit Chin Med Pharm, 2019, 25(19):25-28, 43.

[92] 彭杰,彭建军.中国西北地区野生穿山甲资源现状及药材市场贸易调查[J].林业科技通讯, 2020(3):43-46. Peng J, Peng J J. The wild resources status and medicinal materials market investigation of pangolin (Manis pentadactyla) in the northwest of China[J]. Forest Sci Technol, 2020(3):43-46.

[93] 林永新,郑晓霞,缪伟,等.互联网医疗卫生监督中电子数据取证现状和对策研究[J].中国卫生监督杂志, 2020, 27(4):333-337. Lin Y X, Zheng X X, Miao W, et al. Research on current status and countermeasures of electronic data forensics in internet medical and health supervision[J]. Chin J Health Insp, 2020, 27(4):333-337.

[94] 叶冠成,陈佳祺,张少辉,等.中医互联网医疗发展现状、问题及应对策略探究[J].中国医院, 2023, 27(11):34-39. Ye G C, Chen J Q, Zhang S H, et al. Research on the current situation, problems and countermeasures of internet medical treatment of traditional Chinese medicine[J]. Chin Hosp, 2023, 27(11):34-39.

[95] 龚浩,顾馨雨,杨艳霞,等.我国互联网医疗政策文本分析[J].医学信息学杂志, 2023, 44(3):41-45, 79. Gong H, Gu X Y, Yang Y X, et al. Text analysis of internet medical policy in China[J]. J Med Inform, 2023, 44(3):41-45, 79.

[96] 郑文科,张莉,昝树杰.中药饮片亟需开展临床评价[J].中国中药杂志, 2019, 44(3):624-628. Zheng W K, Zhang L, Zan S J. Urgency of clinical evaluation of traditional Chinese medicine decoction pieces[J]. China J Chin Mater Med, 2019, 44(3):624-628.

[97] 王容,魏屹,周春岚,等.基于指纹图谱结合化学计量法对乌头属藏药材榜那的多指标成分分析[J].中草药, 2020, 51(11):3037-3044. Wang R, Wei Y, Zhou C L, et al. Study on multi-index components of Tibetan medicine Bangna of Aconitum genus according to fingerprints and chemometrics[J]. Chin Tradit Herb Drugs, 2020, 51(11):3037-3044.

[98] 赵露颖,施梦瑶,张巧艳,等.道地药材品质特征及形成机制研究进展[J].中草药, 2022, 53(21):6931-6947. Zhao L Y, Shi M Y, Zhang Q Y, et al. Research progress on quality characteristics and formation mechanism of genuine medicinal materials[J]. Chin Tradit Herb Drugs, 2022, 53(21):6931-6947.

[99] 杨彬,李遇伯,张艳军.基于单细胞转录组学的多基原有毒中药危害识别研究思路及方法[J].中草药, 2021, 52(13):3783-3789. Yang B, Li Y B, Zhang Y J. Research ideas and methods of hazards identification of multi-base source toxic traditional Chinese medicine based on single cell transcriptomics[J]. Chin Tradit Herb Drugs, 2021, 52(13):3783-3789.

[100] 王福,陈士林,刘友平,等.我国中药材种植产业进展与展望[J].中国现代中药, 2023, 25(6):1163-1171 Wang F, Chen S L, Liu Y P, et al. Advances and prospects of Chinese herbal medicine planting industry in China[J]. Mod Chin Med, 2023, 25(6):1163-1171.

[101] 朱颖,宋佩林,周海伦,等.从1.0到4.0的中药炮制技术发展现状评析及展望[J].中国实验方剂学杂志, 2024, 30(1):276-285. Zhu Y, Song P L, Zhou H L, et al. Review and prospect of development status of traditional Chinese medicine processing technology from 1.0 to 4.0[J]. Chin J Exp Tradit Med Form, 2024, 30(1):276-285.

[102] 程玉,余寒优,索芳,等.马兜铃酸减毒与分离方法研究进展[J].中国药业, 2022, 31(7):128-132. Cheng Y, Yu H Y, Suo F, et al. Research progress on attenuated and separated methods of aristolochic acids[J]. China Pharm, 2022, 31(7):128-132.

[103] 杨冰,祝丹丹,于欣茗,等.新世纪20年:守正创新背景下创新炮制技术探索与实践[J].中草药, 2024, 55(2):357-365. Yang B, Zhu D D, Wang X M, et al. Twenty years of new century:Exploration and practice of innovative processing technology under background of uphold fundamental principles and break new ground[J]. Chin Tradit Herb Drugs, 2024, 55(2):357-365.

[104] 马欣荣,王鐾璇,赵万顺,等.数据驱动技术在中药提取智能制造中的应用进展[J].中国中药杂志, 2023, 48(21):5701-5706. Ma X R, Wang B X, Zhao W S, et al. Application progress on data-driven technologies in intelligent manufacturing of traditional Chinese medicine extraction[J]. China J Chin Mater Med, 2023, 48(21):5701-5706.

[105] 刘佳宁,李遇伯,王玉丽,等.基于配伍相互作用的中药合理用药研究进展及监管思考[J].中草药, 2023, 54(2):375-385. Liu J N, Li Y B, Wang Y L, et al. Research progress and supervision considerations of rational medication of traditional Chinese medicine based on compatibility and interactions[J]. Chin Tradit Herb Drugs, 2023, 54(2):375-385.

[106] 陈家琪,包丹丹,张悦,等.附子-大黄药对治疗阳虚类疾病配伍机制研究进展[J].中草药, 2022, 53(11):3518-3530. Chen J Q, Bao D D, Zhang Y, et al.[J]. Research progress on compatibility mechanism of drug pair of Aconiti Lateralis Radix Preparata and Rhei Radix et Rhizoma in treatment of yang deficiency diseases[J]. Chin Tradit Herb Drugs, 2022, 53(11):3518-3530.

[107] 耿晨蕾,王玉玉,刘思佳,等. 3种抗肿瘤有毒蒙药的研究进展[J].中草药, 2023, 54(10):3329-3336. Geng C L, Wang Y Y, Liu S J, et al.[J]. Research progress on three toxic anti-tumor Mongolian medicine[J]. Chin Tradit Herb Drugs, 2023, 54(10):3329-3336.

[108] 王宇佳,杨柱,明雪梅,等.基于Citespace的中药质量标准研究进展分析[J].中国药事, 2022, 36(4):444-451. Wang Y J, Yang Z, Ming X M, et al. Analysis on the progress of Citespace-based Chinese medicine quality standard research[J]. Chin Pharm Aff, 2022, 36(4):444-451.

[109] 刘福梅,王连心,谢雁鸣.中药安全性信号早期发现与风险管控[J].中国中药杂志, 2021, 46(21):5456-5461. Liu F M, Wang L X, Xie Y M. Early detection and risk control of safety signals of Chinese medicine[J]. China J Chin Mater Med, 2021, 46(21):5456-5461.

[110] 王祯,张俊令,焦宏基,等.黄芪有效成分的药理作用与质量控制研究进展[J].药物评价研究, 2023, 46(4):917-924. Wang Z, Zhang J L, Jiao H J, et al. Research progress on pharmacological action and quality control of effective components of Astragali Radix[J]. Drug Eval Res, 2023, 46(4):917-924.

[111] 肖小河.中药安全风险防控:从被动到主动[J].药学进展, 2020, 44(10):721-723. Xiao X H. The safety risks of traditional Chinese medicine:From absence to active[J]. Progr Pharm Sci, 2020, 44(10):721-723.

[112] 房良,吴凌放."健康中国2030"背景下我国中医类医疗服务利用现况研究[J].卫生软科学, 2020, 34(7):69-73, 78. Fang L, Wu L F. Study on the utilization of traditional Chinese medical services under the background of "Healthy China 2030"[J]. Soft Sci Health, 2020, 34(7):69-73, 78.

[113] 宋欣奕.中药注射剂认知、态度和使用行为的调查研究[J].中国高新科技, 2019(11):111-113. Song X Y. Investigation on the cognition, attitude and use behavior of traditional Chinese medicine injections[J]. China High-Tech, 2019(11):111-113.

[114] 姜皓,张晓朦,张冰,等.中药临床应用"禁" "忌" "慎"禁忌用语的认知现状研究[J].中国药房, 2021, 32(3):358-363. Jiang H, Zhang X M, Zhang B, et al. Study on the cognitive status quo of "Prohibiting" "Avoiding" "Using Caution" in the clinical application of TCM[J]. China Pharm, 2021, 32(3):358-363.

[115] 罗超应,罗磐真,李锦宇,等.基于复杂性科学探讨中药安全性评价[J].中华中医药杂志, 2016, 31(8):2929-2932. Luo C Y, Luo P Z, Li J Y, Safety evaluation of traditional Chinese medicine based on complexity science[J]. China J Tradit Chin Med, 2016, 31(8):2929-2932.

[116] 钱文秀,阎星旭,张文青,等.计算机虚拟筛选技术在中药毒性研究中的探索与思考[J].中草药, 2023, 54(12):4036-4043. Qian W X, Yan X X, Zhang W Q, et al. Exploration and thinking of computer virtual screening technology in toxicity research of traditional Chinese medicine[J]. Chin Tradit Herb Drugs, 2023, 54(12):4036-4043.

[117] 蔡嫣然,胡镜清,董继开,等."十四五"我国中医药科技创新平台建设未来态势分析[J].世界科学技术:中医药现代化, 2023, 25(3):820-825. Cai Y R, Hu J Q, Dong J K, et al. Future situation analysis of Chinese traditional medicine technology innovation platform construction in the 14th five-year plan[J]. Mod Tradit Chin Med Mater Med:World Sci Technol, 2023, 25(3):820-825.

[118] 刘慧,许妍妍,谢利娟,等.基于证候理论中药用药禁忌研究概况[J].辽宁中医药大学学报, 2022, 24(3):106-109. Liu H, Xu Y Y, Xie L J, et al. Research survey of contraindications in traditional Chinese medicine based on syndrome theory[J]. J Liaoning Univ Tradit Chin Med, 2022, 24(3):106-109.

[119] 柏兆方,湛小燕,姚清,等.中药安全性评价理论创新与技术突破:病证毒理学[J].中国药物警戒, 2024, 21(1):6-14. Bai Z F, Zhan X Y, Yao Q, et al. Theoretical innovation and technological breakthroughs in the safety evaluation of traditional Chinese medicine:Disease-syndrome-based toxicology[J]. Chin J Pharmacovig, 2024, 21(1):6-14.

[120] 庞立健,吕晓东,石岩,等.基于中医辨证论治理论中药毒性科研思路与方法[J].中华中医药杂志, 2018, 33(2):411-415. Pang L J, Lyu X D, Shi Y, et al. Research ideas and methods of toxicity of Chinese materia medica based on the theory of TCM treatment based on syndrome differentiation[J]. China J Tradit Chin Med Pharm, 2018, 33(2):411-415.

[121] Pasquale C, Pieranna C, Renata S. Advanced technologies in genomic toxicology:Current trend and future directions[J]. Curr Opin Toxicol, 2024, 37:100444.

[122] 朱睿思,李秋红,鞠爱霞.组学及其联用技术在中药毒性研究中的应用分析[J].国际中医中药杂志, 2023, 45(10):1332-1337. Zhu R S, Li Q H, Ju A X. Analysis on the application of omics and its combination technique in toxicity study of Chinese materia medica[J]. Int J Tradit Chin Med, 2023, 45(10):1332-1337.

[123] 贾贝田,刘海朝,王怡杨,等.提升中药材品质紧抓中医临床循证:张伯礼院士谈中医药高质量发展的关键[J].中国中西医结合杂志, 2023, 43(1):21-23. Jia B T, Liu H C, Wang Y Y, et al. Improving quality of Chinese medicinal materials, paying close attention to Chinese medicine clinical evidence:Academician Zhang Bo-li's talking about the key to high-quality development of Chinese medicine[J]. Chin J Integr Tradit West Med, 2023, 43(1):21-23.